Business
Bio-Techne's Ella On The Front Lines In Fight Against COVID-19
MINNEAPOLIS, March 25, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today shared news from clinical partners on the use of the
About this update from Bio-techne Corp
[{"type":"text","content":"MINNEAPOLIS, March 25, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today shared news from clinical partners on the use of the ProteinSimple™-branded Ella™ Automated Immunoassay platform in the fight against COVID-19. \nIn a March 23, 2020 press release, the Icahn School of Medicine, Mount Sinai announced that they are utilizing Bio-Techne's Ella Automated Immunoassay Platform to monitor individual immune responses to COVID-19. Specifically, the Ella Cytokine Storm Panel is being used to detect Cytokine Release Syndrome (CRS) in real-time. Cytokine Release Syndrome represents a critical point in individuals with severe COVID-19 disease where immune molecules, called cytokines, attack the patient's organs, representing a critical and potentially fatal point in disease management. \nAs stated in its press release, \"Mount Sinai clinical laboratories will use the ELLA Cytokine Storm Panel in COVID-19 patients who have been admitted to the hospital to monitor them and know, in real time, when they are experiencing cytokine storm. The test results are available in a few hours and can be repeated throughout the course of care to help guide hospital care and to measure the response to experimental drugs given in clinical trials for COVID-19 patients.\" (link) \"Mount Sinai clinical laboratories will use the ELLA Cytokine Storm Panel in COVID-19 patients who have been admitted to the hospital to monitor them and know, in real time, when they are experiencing cytokine storm. The test results are available in a few hours and can be repeated throughout the course of care to help guide hospital care and to measure the response to experimental drugs given in clinical trials for COVID-19 patients.\"\nMount Sinai joins hospitals in Italy and throughout Europe that have and are continuing to adopt the Ella platform for CRS testing during this crisis. Ella's sensitivity, simplified workflow, and fast time-to-results make the platform ideal for CRS testing and are the key factors driving this adoption. These developments follow the 2018 announcement that Micropoint Biotechnologies of China is developing clinical applications for the detection of CRS on the Ella platform. \n\"Ella is a potentially important tool for monitoring and saving patients who are infected by COVID-19,\" commented Chuck Kummeth, President and Chief Executive Of...